Premium
Significant association between human osteosarcoma and simian virus 40
Author(s) -
Mazzoni Elisa,
Benassi Maria Serena,
Corallini Alfredo,
BarbantiBrodano Giovanni,
Taronna Angelo,
Picci Piero,
Guerra Giovanni,
D'Agostino Antonio,
Trevisiol Lorenzo,
Nocini Pier Francesco,
Casali Maria Vittoria,
BarbantiBrodano Giuseppe,
Martini Fernanda,
Tog Mauro
Publication year - 2015
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29137
Subject(s) - nasopharyngeal carcinoma , medicine , antibody , osteosarcoma , antigen , virus , cancer , epitope , carcinoma , clinical significance , immunology , virology , oncology , cancer research , radiation therapy
BACKGROUND Simian virus 40 (SV40) has been considered to be an oncogenic viral agent in the development of osteosarcoma (OS), which to the authors' knowledge continues to be of unknown etiology. METHODS In the current study, serum samples from patients with OS were investigated with an indirect enzyme‐linked immunoadsorbent assay (ELISA) to test for the presence of immunoglobulin G antibodies, which react with SV40 antigens. In ELISA, SV40 antigens were represented by 2 synthetic polypeptides that mimic epitopes of the viral capsid proteins 1 to 3. Additional sera from patients with breast cancer and undifferentiated nasopharyngeal carcinoma as well as healthy subjects were the controls. RESULTS Immunologic results suggested that antibodies that react with SV40 mimotopes were more prevalent (44%) in serum samples from patients with OS compared with healthy subjects (17%). The difference in prevalence between these cohorts was statistically significant ( P <.001). It is interesting to note that in the patients with OS, significance indicated the difference between OS versus breast cancer (44% vs 15%; P <.001) and OS versus undifferentiated nasopharyngeal carcinoma (44% vs 25%; P <.05). CONCLUSIONS The data from the current study indicate an association between OS and SV40. These data could be transferred to clinical applications for innovative therapies to address SV40‐positive OS. Cancer 2015;121:708–715. © 2014 American Cancer Society .